SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
EXACT Sciences (NASDAQ: EXAS): Buy and Hold for Long-Term Upside
EXAS
|
|
|
+3.04%
in
15 days
EXACT Sciences (NASDAQ: EXAS) is a molecular diagnostics company that is developing a next-generation (V3), stool DNA (sDNA) based screening test for colorectal cancer (CRC) which has demonstrated the ability to detect both early-stage cancer and pre-cancerous growths. The Company's sDNA-based screening technology platform has also demonstrated the ability to detect related GI cancers and pre-cancers. <> Only 24% of an estimated 90 million individuals in the U.S. are currently compliant with CRC screening recommendations, which results in an estimated 68 million people who are non-compl...
|
EXACT Sciences (NASDAQ: EXAS): Patience Required for Long-Term Upside
EXAS
|
|
|
+6.48%
in
4 days
(closed on 11/07/09)
On 11/3/09, EXACT Sciences (NASDAQ: EXAS) reported its 3Q09 results and held a conference call to outline the Company’s progress and timeline for the development of a stool DNA based test kit for the early diagnosis and prevention of colorectal cancer (CRC). EXAS reported total revenue of $1.3 million (which primarily reflects non-cash recognition of Genzyme deal earlier this year), a net loss of $1 million, operating expenses of $2.3 million, and ended the quarter with cash / equivalents of $26.9 million. <> Last week, EXAS made a SEC 8-K filing regarding its President / CEO,...
|
BioMed News Bytes: Rockwell Medical, EXACT Sciences, MannKind
EXAS
|
|
|
-0.81%
in
5 days
(closed on 11/03/09)
BioMed News Bytes: Rockwell Medical, EXACT Sciences, MannKind The BioMedReports.com FDA Calendar service includes a database with over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results. <> On 10/29/09, MannKind (NASDAQ: MNKD) announced that results of two Phase 1 studies demonstrate that the novel, investigational ...
|
BioMed News Bytes: Cytori, EXACT Sciences, HEPI
EXAS
|
|
|
-9.45%
in
26 days
(closed on 10/29/09)
Cytori Therapeutics (NASDAQ: CYTX) has launched a new website at http://www.cellenrich.eu to help educate and raise awareness amongst patients and physicians on cell-enriched cosmetic surgery procedures. Also check out the ProActive News Room website / blog for Cytori and email me if you are interested in becoming a contributing author. <o:p> </o:p> <o:p> </o:p> <> <> On 10/2/09, Health Enhancement Products (OTC: HEPI.OB) and Changing Times Vitamins announced a mutual agreement to terminate their current distribution agreement in which the latter had ac...
|
Rodman Conference Recaps: EXACT Sciences, Delcath, Unilife
EXAS
|
|
|
-6.46%
in
20 days
(closed on 10/03/09)
<> <> On 8/31/09, Delcath Systems (NASDAQ:DCTH) announced the FDA granted orphan drug status to doxorubicin, an approved chemotherapy agent, for the treatment of primary liver cancer. The Company said it tested doxorubicin with its unique drug delivery technology, Percutaneous Hepatic Perfusion (PHP), which results in significantly higher doses (e.g. 10X the FDA approved standard dosing with 100X exposure of drug to the tumor site) of anti-cancer drugs such as doxorubicin to the liver without exposing the patient's entire body. Delcath plans to carry out the necessary clinical work for a regul...
|
From the Blogosphere
EXACT Sciences Shows Strong Breakout
The technical breakout I thought we might see in EXACT Sciences (EXAS) is now in full gear. EXACT shares are up about 70% since the last post, and over 300% off December lows. Technically, part of the bounce is simply a matter of seller exhaustion. But its a lot more than that. Since December, EXACT Sciences received a huge cash infusion from Genzyme (GENZ), upgraded its management team, and regained Nasdaq compliance.
|
New Website Coming Soon!
|
|
|
A new website for healthcare investors and traders should be ready to launch by the end of February, which is designed to provide users with more features beyond my current blog format.
The site will feature its own blog, discussion forum, news feeds, videos, stock commentaries (including multiple contributors), and other unique content – including my FDA and Clinical Trial Calendars plus a database that includes hundreds of foreign and U.S.-listed stocks in the healthcare sector which are organized into unique indexes, including:
1.) Emerging Stem Cell Research – StemCells (STEM)< />< />< />< />< />< />< />< />< />< />< />< /><><>< />< /><>< />< /><>< />< /><>< />< />< />< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><><><>< /><><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< />< />...
|
Cell Therapeutics: Down, but Not Out
|
|
|
Cell Therapeutics (CTIC) is a micro-cap cancer biotech which is down substantially in the past year in terms of stock price and market value, but not out after recently establishing a joint venture with Spectrum Pharma (SPPI) to market Zevalin, the potential for two FDA approvals this year (one new product, one label expansion), the potential for EMEA approval of Opaxio in the E.U., and a goal to become cash flow break-even by year-end.
A World Health Organization report released late last year estimates that cancer will overtake heart disease as the top cause of death in the world by 2010, ...
|
Create Your Own Diagnostics ETF
|
|
|
With HealthShares closing shop at year-end, including the former Diagnostics fund, investors who are interested in the space can create their own ETF comprised of companies from the ETF Innovators Preventive Medicine and Emerging Diagnostics Indexes. Below is a list of companies which have stocks listed for trading in the U.S. at over $1/share with a market cap of less than $10B, focusing on smaller companies which are more leveraged to diagnostics and represent possible takeover targets for larger players such as Roche (RHHBY), Abbott Labs (ABT), and Johnson & Johnson (JNJ).
However, the sm...
|
New Preventive Medicine Index
|
|
|
One of the major reasons behind Pfizer's (PFE) interest in acquiring Wyeth (WYE) is the latter's focus on products outside of traditional pharmaceuticals – with 60% of Wyeth's revenue from last year derived from biological therapeutics and vaccines. It remains to be seen what happens to Wyeth's proposed deal to acquire Dutch vaccine maker Crucell (CRXL); however since it is much smaller (around $1B) and focuses on the development of vaccines, Pfizer would likely be interested in both companies together.
With the focus on preventive medicine likely continue in the form of continued M&A...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on EXAS |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About EXACT Sciences Corp.
- Answers.com
